SGLT2 inhibitors and their role in reducing mortality among cancer patients with type 2 diabetes undergoing immune checkpoint inhibitor therapy
{{output}}
Patients with type 2 diabetes mellitus (T2DM) and cancer undergoing immune checkpoint inhibitor (ICI) therapy face increased risks due to the convergence of metabolic, cardiovascular, and immune-related complications. Recent retrospective data suggest that sod... ...
